- March 2020 – Tel Aviv, Israel
- Genetics of MDS – Rafael Bejar
Innate Immunity in MDS Pathogenesis – Alan List
Etiology and Epidemiology – Drorit Merkel
Lessons from the EUMDS Registry – Theo de Witte
MicroRNA Signature in Myelodysplastic Syndrome – Inga Mandac Rogulj; Marjana M. Kardum Paro; Slobodanka Ostojic Koloni
Noninvasive Diagnosis of Myelodysplastic Syndromes (MDS) – Howard S. Oster; University/EUMDS
Patient Case – Drorit Merkel
Paient Discussion Forum – Merav Barzilai
Iron Chelation and Targeted Therapy in MDS, Shifting the Treatment Paradigm – Emanuele Angelucci
The Impact of Comorbidities and Infections in the Course and Prognosis of MDS – Argiris Symeonidis
Optimizing Transfusion Support in MDS. Is What We Are Doing What Patients Want? – Rena Buckstein
Molecular and Clinical Classifications of MDS – Peter Greenberg
The Iron man: when tissue is the issue – Maya Zlotnick
High-Risk MDS Patient – Mika Geva
Allogeneic Hematopoietic Stem Cell Transplant – Theo de Witte
Paient Discussion Forum – May Basood
Systemic inflammatory manifestations in a young adult – Nicolas Bonadies
Patient Case – Galia Stemer
Hypomethylating agents in MDS – Pierre Fenaux
Beyond HMA (I) – Combinations Therapies in MDS – Mikkael Sekeres
Precision Medicine in 2020 – Stephen Nimer
Patient Case – Rotem Keidar
Paient Discussion Forum – Moshe Mittelman
Approach to the Patient with MDS Refractory to Hypomethylating Agents(HMA) – Kalman Filanovski